Market Research Report
Global Erythropoietin Drugs Market Insights and Forecast to 2028
|Global Erythropoietin Drugs Market Insights and Forecast to 2028|
Published: January 20, 2022
Content info: 93 Pages
Delivery time: 2-3 business days
Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with the peritubular capillary and proximal convoluted tubule.
Market Analysis and Insights: Global Erythropoietin Drugs Market
Due to the COVID-19 pandemic, the global Erythropoietin Drugs market size is estimated to be worth US$ 9734.1 million in 2022 and is forecast to a readjusted size of US$ 13560 million by 2028 with a CAGR of 5.7% during the review period. Fully considering the economic change by this health crisis, Epoetin-alfa accounting for % of the Erythropoietin Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Anemia segment is altered to an % CAGR throughout this forecast period.
The retail pharmacies segment dominated the erythropoietin drugs market and accounted for a major part of the overall market share. The ability of retail pharmacies to provide a large customer base for biosimilars coupled with the requirement from anemic patients for EPO drugs as a maintenance therapy is the key contributor to the dominance of this segment in the global market.
Global Erythropoietin Drugs Scope and Segment
Erythropoietin Drugs market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Erythropoietin Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Segment by Application